PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: The Scott Partnership

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Thermo Fisher Scientific Wins R&D 100 Award - Thermo Fisher Scientific wins R&D 100 Award for revolutionary three-minute cold disinfection solution (NYSE: TMO)
Thermo Fisher Scientific Wins R&D 100 Award

 

NewswireToday - /newswire/ - Runcorn, Cheshire, United Kingdom, 2010/08/24 - Thermo Fisher Scientific wins R&D 100 Award for revolutionary three-minute cold disinfection solution (NYSE: TMO).

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Thermo Fisher Scientific, Inc., the world leader in serving science, today announced that its Thermo Scientific HM550 Cryostat with cold disinfection has been chosen as an R&D 100 award winner by an independent judging panel and the editors of R&D. The award recognizes the HM550 Cryostat as one of the most technologically significant products to enter the marketplace this year. The system distinguished itself among other entries due to its ability to dramatically reduce laboratory staff health risks as they interact with live cells and infectious tissues. This benefit is a direct result of the instrument’s capability to instantly disinfect the entire cryo chamber in three minutes.

Alternative methods of disinfection require a minimum two-hour warm-up period followed by a 30-minute disinfection process, or UV light which also takes at least 30 minutes. In comparison, cold disinfection efficiently removes aerobic bacteria and fungi in only three minutes. In addition to improving the safety of laboratory work conditions, the speed of cold disinfection dramatically reduces work flow interruption, as the HM550 Cryostat is safe to use directly after the disinfection process is complete. This new cold disinfection technology functions 100-times faster than previously existing disinfection methods, greatly increasing efficiency and overall throughput.

The Thermo Scientific HM550 Cryostat’s pioneering cold disinfection technology uses Sanosil® (Sanosil Ltd., Switzerland), a strong disinfectant and virucide that is proven to be 99.99 percent effective when fighting more than 144 pathogens. As a result, users can confidently work with the knowledge that their cryostat is hygienic and safe. The R&D 100 award also acknowledged that unlike other methods of chemical disinfection, which can produce toxic compounds that are dangerous when inhaled in high concentrations, Sanosil is non-toxic and non-carcinogenic, ensuring the health and safety of lab technicians.

“We are delighted to have been selected for the R&D 100 Award. Thermo Fisher Scientific recognizes the invaluable service provided by laboratory staff, and the development of the HM550 Cryostat is a testament to our commitment in ensuring continued safety within all laboratories,” said Giulio Cerroni, vice president of commercial operations for anatomical pathology in Europe, the Middle East and Asia Pacific at Thermo Fisher Scientific. “The competition has been particularly strong this year so it is a great compliment to the Thermo Scientific HM550 Cryostat with cold disinfection to be acknowledged by industry leaders as one of the most valuable and significant products released to the market.”

R&D will honor the Thermo Scientific HM550 Cryostat project team during a Gala Awards Banquet on November 11, 2010 in Orlando, Florida.

For more information about the new Thermo Scientific HM550 Cryostat with cold disinfection, please call +44 (0)800 018 9396

Sanosil is a registered trademark of Sanosil Ltd.

Thermo Scientific is part of Thermo Fisher Scientific, the world leader in serving science.

About Thermo Fisher Scientific
Thermo Fisher Scientific, Inc. (NYSE: TMO) is the world leader in serving science. Our mission is to enable our customers to make the world healthier, cleaner and safer. With revenues of more than $10 billion, we have approximately 35,000 employees and serve customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as in environmental and process control industries. We create value for our key stakeholders through two premier brands, Thermo Scientific and Fisher Scientific, which offer a unique combination of continuous technology development and the most convenient purchasing options. Our products and services help accelerate the pace of scientific discovery, and solve analytical challenges ranging from complex research to routine testing to field applications.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: The Scott Partnership

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Thermo Fisher Scientific Wins R&D 100 Award

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Laura Browne - Scottpr.com 
+44 1477 539539 pathology[.]scottpr.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any The Scott Partnership securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From The Scott Partnership / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe
BTG and Mirada Medical Announce CE Mark Certification for Simplicit90Y Dosimetry Software in Europe
FDA Grants Priority Review to Genentech’s Lucentis® (Ranibizumab Injection) Supplemental Biologics License Application
Genentech’s TECENTRIQ® (Atezolizumab) Shows Significant Survival Advantage Compared to Chemotherapy

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  NAKIVO, Inc.

Visit  La Bella Bakery Artisan Bakery Arizona





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)